Payment overview · 2025
General Payments
$638.15
26 reported records · 10 companies
Healthcare provider profile · identity verified
Nicholas Z Okeson, DO
Allopathic & Osteopathic Physicians|Family Medicine · LARGO, FL · NPI 1023058237
Verified facts
What the public records show
CMS Open Payments records show Nicholas Z Okeson, DO received $638.15 in general payments during 2025 across 26 reported records.
Gilead Sciences, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $125.95 | 19.7% | 4 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $121.79 | 19.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.65 | 13.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.20 | 11.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.87 | 10.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.24 | 8.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.24 | 6.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.31 | 4.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.24 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.66 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.15 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $121.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.11 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.85 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.85 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.24 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 234 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 53 |
| Losartan Potassium | Losartan Potassium | 193 | 55 |
| Lisinopril | Lisinopril | 192 | 51 |
| Alprazolam | Alprazolam | 190 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 53 |
| Omeprazole | Omeprazole | 155 | 41 |
| Metformin Hcl | Metformin Hcl | 154 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 40 |
| Tramadol Hcl | Tramadol Hcl | 138 | 28 |
| Furosemide | Furosemide | 133 | 45 |
| Gabapentin | Gabapentin | 128 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 40 |
| Prednisone | Prednisone | 107 | 79 |
| Allopurinol | Allopurinol | 101 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 23 |
| Meloxicam | Meloxicam | 90 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 24 |
| Clonazepam | Clonazepam | 89 | 12 |
| Lorazepam | Lorazepam | 88 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 88 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 22 |
| Bupropion Xl | Bupropion Hcl | 85 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 26 |
| Baclofen | Baclofen | 77 | 33 |
| Celecoxib | Celecoxib | 76 | 21 |
| Famotidine | Famotidine | 71 | 24 |
| Eliquis | Apixaban | 68 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 12 |
| Montelukast Sodium | Montelukast Sodium | 62 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Simvastatin | Simvastatin | 61 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 20 |
| Potassium Chloride | Potassium Chloride | 57 | 15 |
| Temazepam | Temazepam | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 14 |
| Amoxicillin | Amoxicillin | 51 | 39 |
| Ondansetron Odt | Ondansetron | 51 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 44 |
| Sildenafil Citrate | Sildenafil Citrate | 46 | 14 |
| Diazepam | Diazepam | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 12 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 11 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 15 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 14 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Cefdinir | Cefdinir | 20 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $638.15 · 26 records | Gilead Sciences, Inc. | AIRSUPRA, Barostim Neo System, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error